ethambutol has been researched along with lomefloxacin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Dempsey, S; Jack, C; Miller, CH; Nisa, S; O'Toole, R | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bai, L; Deng, JL; Gao, F; Lv, ZS; Wang, Y; Xu, Z; Zhang, F; Zhao, SJ | 1 |
| Koriakin, VA; Kunichan, AD; Lazareva, IaV; Sokolova, GB | 1 |
| Dolgushin, MV | 1 |
2 review(s) available for ethambutol and lomefloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Fluoroquinolone-isatin hybrids and their biological activities.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Antitubercular Agents; Antiviral Agents; Fluoroquinolones; Humans; Isatin; Structure-Activity Relationship | 2019 |
1 trial(s) available for ethambutol and lomefloxacin
| Article | Year |
|---|---|
[Lomefloxacin in complex treatment of acute progressive form of pulmonary tuberculosis].
Topics: Acute Disease; Adolescent; Adult; Animals; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Mice; Middle Aged; Pyrazinamide; Quinolones; Streptomycin; Treatment Outcome; Tuberculosis, Pulmonary | 1998 |
3 other study(ies) available for ethambutol and lomefloxacin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
Topics: Antitubercular Agents; Cysteine; Drug Evaluation, Preclinical; Mycobacterium; Mycobacterium smegmatis; Organoselenium Compounds; Selenocysteine; Small Molecule Libraries | 2009 |
Cytochemical Evaluation of the Toxic Effects of Combined Antituberculosis Substances on Metabolic State of Blood Lymphocytes.
Topics: Acid Phosphatase; Administration, Oral; Animals; Animals, Outbred Strains; Antitubercular Agents; Drug Combinations; Esterases; Ethambutol; Fluoroquinolones; Gene Expression; Glycerolphosphate Dehydrogenase; Isoniazid; L-Lactate Dehydrogenase; Lymphocytes; Male; Primary Cell Culture; Prothionamide; Pyrazinamide; Rats; Rifampin; Succinate Dehydrogenase | 2020 |